Epilepsy affects as many as 80%--90% of patients with tuberous sclerosis complex (TSC).^[@R1],[@R2]^ Approximately, 60% of these become refractory to conventional antiepileptic drugs (AEDs),^[@R3]^ which highlights the need for development of more effective treatments. Dysregulation and overactivation of the mammalian target of rapamycin (mTOR) pathway due to mutations in either the *TSC1* or *TSC2* genes are causally linked to the cortical malformations, intellectual disability, and epilepsy in TSC.^[@R4]^ Preclinical and preliminary clinical studies have demonstrated seizure reduction and potential disease-modifying effects of mTOR inhibitors in patients with TSC experiencing epilepsy.^[@R1],[@R5][@R6][@R8]^ Everolimus, an oral mTOR inhibitor, was investigated as an adjunctive therapy for the treatment of refractory seizures associated with TSC in the EXIST-3 trial.^[@R9]^ The 2 trough exposure ranges of everolimus used in the study (3--7 ng/mL \[low exposure (LE)\] and 9--15 ng/mL \[high exposure (HE)\]) were superior to placebo for the coprimary end points of 50% response rate (RR, 28.2% and 40% vs 15.1%) and median percentage reduction (PR) in seizure frequency (SF, 29.3% and 39.6% vs 14.9%), during the 12-week maintenance period of the core phase.^[@R9]^ There has been a growing interest in understanding what happens when patients with TSC are maintained on everolimus in the longer term for the following reasons. The first is a concern regarding whether there are additional risks when maintaining treatment over a longer duration. The second is whether seizure improvement persists or potentially increases over time since everolimus addresses the underlying pathophysiology of epileptogenicity in TSC, rather than only suppressing seizures. In this study, we report the long-term efficacy and safety of everolimus from the EXIST-3 study when all patients have completed ≥48 weeks of the extension phase of the study.

Methods {#s1}
=======

Study design and procedures {#s1-1}
---------------------------

The design of the prospective, randomized, double-blind, parallel-group EXIST-3 study has been described previously.^[@R9]^ In the core phase, eligible patients were randomized to receive placebo, everolimus LE, or everolimus HE in addition to a stable regimen of 1--3 AEDs. After the core phase, patients remaining on study were eligible to continue in the extension phase for ≥48 weeks. Maintenance of blinding was preserved during transition to the extension phase by adding the possibility of placebo tablet administration to patients initially randomized to placebo or everolimus LE groups. Investigators were permitted to make their own dose titrations within the targeted trough concentration (C~min~) range of 3--15 ng/mL after a transition period to a common target C~min~ of 6--10 ng/mL implemented by Interactive Response Technology software to further maintain the blinded nature of the core phase. Rescue medication was allowed in patients with a transient increase in seizure activity but for not more than 14 cumulative days during any 12-week period. Investigators were also permitted to change AEDs or modify the dose of AEDs during the extension phase. Everolimus blood trough levels were measured at weeks 19, 22, 26, and 30, and every 12 weeks thereafter to allow dose adjustments to achieve the target C~min~ range and also measured 2 weeks after a change in everolimus dose, addition or change in the dose of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein inducer or inhibitor. Patients or caregivers continued to record seizures in seizure diaries throughout the extension phase. Patients continuing to receive clinical benefit at the completion of the extension phase were eligible to continue everolimus in a postextension phase of EXIST-3 (NCT02962414).

End points {#s1-2}
----------

The efficacy end points included change from baseline in SF over time, expressed as RR (percentage of patients with ≥50% reduction in SF) and median PR in SF, determined at 12-week intervals throughout the duration of everolimus treatment. Additional exploratory end points were change from baseline in seizure-free days, exposure-efficacy relationship analysis, safety (frequency of adverse events \[AEs\] assessed according to the Common Terminology Criteria for AEs, version 4.03), and exposure-safety relationship analysis. Post hoc exploratory efficacy end points assessed the emergence of new responders over time, time to the first 12-week response, and analysis of the persistent responses. Seizure types included in the analysis were described in the report of the core phase of the study.^[@R9]^

Statistical analysis {#s1-3}
--------------------

Evaluable patients included those who received ≥1 dose of everolimus in the core or extension phases of the study and had ≥1 efficacy or safety assessment. Patients were analyzed as a single everolimus-treated group and analyzed separately according to their initial randomization group (patients originally randomized to placebo entering the extension phase with a target everolimus C~min~ of 3--15 ng/mL, everolimus LE, and everolimus HE groups). The efficacy end points of RR, PR from start of everolimus in SF, and change from start of everolimus in seizure-free days were determined by 12-week time windows from week 7 after the start of everolimus (from randomization for patients randomized to everolimus and from start of everolimus in the extension phase for patients initially randomized to placebo): from week 7--18, then from week 19--30, and every 12 weeks thereafter. An analysis was performed classifying patients who discontinued everolimus either in the core or extension phases as nonresponders in the time window in which seizures would have been recorded if the patient had not discontinued early. The time to first 12-week response was defined as the time from the start of everolimus until the last day of the first 12-week period when the patient achieved a response (50% of seizure reduction). A persistent response was defined as a response occurring during any 12-week interval with no subsequent change to a nonresponder status as of the cutoff date. The change in SF was calculated by 12-week and 2-week time intervals and by 2-week time interval for seizure-free days from randomization. Additional details on statistical methodology used to assess the relationship between efficacy, safety, and exposure to everolimus can be found in appendixes e-1 and e-2 ([links.lww.com/CPJ/A46](http://links.lww.com/CPJ/A46)). Statistical analysis was performed with SAS (version 9.2).

Standard protocol approvals, registrations, and patient consents {#s1-4}
----------------------------------------------------------------

All patients (or their legal representatives) provided written informed consent before entering the baseline phase. The study was conducted in accordance with the principles of Good Clinical Practice, the Declaration of Helsinki, and all local regulations. The study protocol and all amendments were reviewed and approved by independent ethics committees or institutional review boards for each center. The study is registered with [clinicaltrials.gov](http://clinicaltrials.gov) (NCT01713946).

Classification of evidence {#s1-5}
--------------------------

This interventional study (extension phase) provides Class IV evidence that a sustained effect was observed with everolimus treatment as an adjunctive therapy for the treatment of refractory seizures associated with TSC. Reductions in SF tended to increase over time and were more prominent in patients with greater exposure to the study drug. Adverse events were similar to those described in previous trials of everolimus in TSC patients for nonepileptic disease manifestations.

Data availability {#s1-6}
-----------------

Novartis supports the publication of scientifically rigorous analysis that is relevant to patient care, regardless of a positive or negative outcome. Qualified external researchers can request access to anonymized patient-level data, respecting patient-informed consent, through [clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com/), according to requirements noted on the Web portal.

Results {#s2}
=======

Of the 366 patients enrolled (placebo-randomized patients \[n = 119\], everolimus LE \[n = 117\], everolimus HE \[n = 130\]), 361 received ≥1 dose of everolimus either in the core or extension phases. Five patients randomized to placebo discontinued the study during the core phase, and thus did not enter the extension phase. At the data cutoff date (September 2, 2016), 256 patients continued to receive everolimus; the primary reasons for discontinuation were AEs (12.7%), withdrawal of consent (7.2%), and lack of efficacy (5.8%; [figure 1](#F1){ref-type="fig"}). Ninety-five patients (26.3%) discontinued everolimus before achieving 2 years of follow-up and 103 (28.5%) had \<2 years of follow-up at the time of this analysis. The median age at the start of everolimus was 10 years (n = 361) with 28% of patients aged \<6 years, 81.4% aged \<18 years, and 18.6% aged ≥18 years ([table 1](#T1){ref-type="table"}). The median duration of everolimus exposure was ∼21 months (90.4 weeks; range, 2--165), and the median dose intensity was 6.76 mg/m^2^/day (range, 1.1--27.8).

![Trial profile\
AED = antiepileptic drug; IRT = investigator/research team.](NEURCLINPRACT2017025403FF1){#F1}

###### 

Patient demographics, disease characteristics, previous and concomitant AEDs, and rescue medication
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![](NEURCLINPRACT2017025403TT1A)

RRs increased over time from the start of everolimus treatment: from 31% (95% CI, 26.2--36.1) at week 18 (weeks 7--18, n = 352) to 46.6% (95% CI, 40.9--52.5) at 1 year (weeks 43--54, n = 298), and to 57.7% (95% CI, 49.7--65.4) at 2 years of everolimus exposure (weeks 91--102, n = 163; [figure 2A](#F2){ref-type="fig"}). To account for patients\' dropout during the study, an analysis considering withdrawn patients as nonresponders was conducted. This analysis showed an RR of 30.2% (95% CI, 25.5--35.2) at week 18 (n = 361), 38.8% (95% CI, 33.7--44.1) at 1 year (n = 358), and 41.0% (95% CI, 34.6--47.7) at 2 years of everolimus exposure (n = 229). Efficacy analysis from randomization restricted to evaluable patients at 1 year also demonstrated a sustained reduction in SF (figure e-1, [links.lww.com/CPJ/A47](http://links.lww.com/CPJ/A47)). Consistent with the RR, the PR in weekly SF improved over time from 31.7% (95% CI, 28.5--36.1) at week 18 to 46.7% (95% CI, 40.2--54.0) at 1 year, and to 56.9% (95% CI, 50--68.4) at 2 years of everolimus exposure ([figure 2B](#F2){ref-type="fig"}). Despite a common target exposure range in the extension phase, the greatest benefit was observed in patients initially randomized to the everolimus HE group, whereas placebo-randomized patients and patients randomized to everolimus LE had a similar pattern of efficacy outcomes over time (figure e-2A). Across all treatment groups, the median weekly SF decreased from 8.6 at the start of everolimus to 3.6 and from 7.1 at the start of everolimus to 2.3 at 1 and 2 years of everolimus exposure, respectively. The median number of additional seizure-free days (per 28-day period) increased from 2.5 days at week 18 to 4.32 days at 1 year and 6.15 days at 2 years of everolimus exposure. The number of patients who were seizure-free over the previous 6 months remained roughly the same at 1 and 2 years although the proportion of patients increased from 5% (15/275) to 11% (13/117), respectively because of the difference in the denominator ([table 2](#T2){ref-type="table"}). The likelihood of observing a 50% of reduction in SF (calculated during a 12-week period) 1 year after the start of everolimus was 45% in patients who transitioned from placebo to everolimus in the extension phase, 55% in everolimus LE, and 70% in the everolimus HE group. Fifty percent of patients experienced a persistent response and 59% of these had persistent responses lasting for ≥48 weeks. Similarly, an increase in the number of seizure-free days was observed in the LE and HE groups; for placebo-randomized patients, the number of seizure-free days was similar to that observed in LE group (figure e-2B). The proportions of patients receiving 1, 2, 3, and \>3 AEDs at baseline (10.8%, 41.6%, 46.8%, and 0.8%) were comparable to the proportions of patients receiving the same numbers of concomitant AEDs at week 18 (10.8%, 39.5%, 47.7%, and 2%), 1 year (10.7%, 36.7%, 48.3%, and 4%), and 2 years (6.7%, 39.3%, 46.6%, and 4.9%), respectively of everolimus exposure. Forty-seven percent of patients received the same AED regimen for ≥54 weeks after the start of everolimus. Exposure-efficacy analysis suggested that reductions in SF were both time and exposure dependent. Higher everolimus exposure, lower baseline SF, and longer treatment duration were associated with a lower postbaseline SF. However, the effect of longer treatment duration on further increases in efficacy seems to be modest (appendix e-1, [links.lww.com/CPJ/A46](http://links.lww.com/CPJ/A46)).

![Seizure outcomes\
(A) Response rate over time from the start of everolimus. Bars represent 95% confidence intervals obtained using Clopper-Pearson method. (B) Median percentage reduction in seizure frequency over time from the start of everolimus. Bars represent 95% confidence intervals based on bootstrap percentiles.](NEURCLINPRACT2017025403FF2){#F2}

###### 

Seizure freedom rates over time
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The most frequent all-grade AEs due to any cause, reported in \>20% of patients throughout the study included stomatitis (35.2%), pyrexia (34.6%), diarrhea (28.5%), mouth ulceration (27.7%), nasopharyngitis (23.8%), and upper respiratory tract infection (22.4%). Grade 3 or 4 AEs were reported in 40.2% of patients, the most frequent were pneumonia (6.9%), status epilepticus (3.3%), seizures (2.8%), and stomatitis (2.5%; [table 3](#T3){ref-type="table"}). Overall, 5.3% of patients experienced grade 4 AEs; the most common were status epilepticus, pneumonia (3 patients each), and neutropenia (2 patients). The incidence of new or changed grade 3 or 4 AEs during the second year (period between 12 and 24 months) of everolimus seemed to be similar to that observed within the first 6 months of treatment (≤6 months, 21.6%; \>6--12 months, 13.8%; second year, 19.9%; third year, 4.7%). However, at the data cutoff date, fewer than 40% of patients completed a 2-year exposure to everolimus, preventing a definitive interpretation of these results. The most frequent treatment-related AEs reported were stomatitis (33.5%), mouth ulceration (26.0%), diarrhea (10.5%), aphthous ulcer (10.2%), and pyrexia (10.2%). Serious AEs were reported in 33.2% of patients, and the most frequent were pneumonia (9.1%), seizure (4.2%), and status epilepticus (3.6%). In addition, there was no apparent increase in the emergence of all-grade treatment-related AEs over time (≤6 months, 77.8%; \>6--12 months, 46.2%; second year, 45.5%). Adverse events led to treatment discontinuation in 47 patients (13%), primarily because of pneumonia (1.7%) and stomatitis (1.4%). The most common AEs necessitating dose adjustments or interruption were stomatitis (9.4%), mouth ulceration (9.1%), pyrexia (6.1%), and pneumonia (5.3%). Menstrual irregularities were reported in 12 patients (3.3%). Exposure-safety relationship analysis outcomes are provided in appendix e-2, [links.lww.com/CPJ/A46](http://links.lww.com/CPJ/A46). The exposure to everolimus, expressed as time-normalized (TN) C~min~ up to the first grade 3/4 event or up to the last dose of everolimus, was similar between patients who reported grade 3/4 AEs and patients who did not report grade 3/4 AEs. There were 4 patients with TN C~min~ \>15 ng/mL: 3 reported grade 3 and 4 events, but none reported unexpected toxicities or safety concerns ([table 4](#T4){ref-type="table"}). Two deaths occurred during the extension phase---both in pediatric patients---because of pneumonia (suspected to be treatment related) and sudden unexpected death in epilepsy (SUDEP, not suspected to be treatment related). Two additional deaths occurred after the data cutoff date, 1 in a child because of septic shock (suspected to be treatment related) and other in an adult patient because of SUDEP (not suspected to be treatment related).

###### 

Adverse events of any cause reported in ≥10% of patients (N = 361)
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###### 

First occurrence of grade 3/4 adverse events by treatment phase and by time-normalized C~min~
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Discussion {#s3}
==========

In this prospective phase 3 trial, treatment with everolimus as an adjunctive therapy for nearly 2 years produced clinically relevant and sustained reductions in SF over time in patients with treatment-refractory seizures associated with TSC. During the core phase, RRs achieved with everolimus LE and HE were 28.2% and 40%, and the median PR were 29.3% and 39.6%, respectively.^[@R9]^ A substantial benefit was demonstrated with continuous use of everolimus. The treatment effect was sustained over time (RR and median PR at week 18, 1 year, and 2 years of everolimus exposure were 31%, 46.6%, 57.7%, and 31.7%, 46.7%, 56.9%, respectively). However, the number of evaluable patients reduced over time. Our study results are consistent with the long-term efficacy data reported in an open-label trial of everolimus for intractable epilepsy for up to 4 years wherein the seizure RRs increased over time (76%, 75%, 80%, and 93% of RR at 12, 24, 36, and 48 months, respectively).^[@R10]^ However, the study had a modest sample size (20 patients). EXIST-3 is the first phase 3 placebo-controlled epilepsy trial in a large population of patients with TSC (N = 366), including high-risk patients. EXIST-3 results are consistent with another open-label trial (15 patients), which demonstrated efficacy of everolimus in patients with TSC and epilepsy.^[@R11]^ In EXIST-3, new responders emerged with a longer everolimus treatment duration and 50% of patients experienced persistent responses. Although a large number of patients (n = 202) had achieved 2 years of treatment follow-up, there was a decreasing number of evaluable patients over time. Ninety-five patients discontinued everolimus before achieving 2 years of follow-up, and 103 patients did not attain the 2 years of follow-up at the time of data cutoff. Some degree of dropout is expected in patients with refractory epilepsy during long-term therapy as evidenced by earlier large multicenter trials of AEDs.^[@R12]^ Nevertheless, a conservative analysis, which considered patients who discontinued treatment as nonresponders, confirmed the sustained efficacy of everolimus over time and suggested that once patients have responded, the efficacy of everolimus is typically maintained. In addition, the median weekly SF decreased during 2 years of treatment and the number of patients who were seizure-free over the previous 6 months remained roughly the same at 1 and 2 years while the proportion of patients increased from 5% after 1 year to 11% after 2 years.

In this study, prompt and robust reductions in SF were observed soon after transitioning to everolimus in the extension phase from placebo, suggesting additional SF reduction achieved beyond the placebo effect observed in the core phase. Despite the goal of achieving a common target exposure range of 3--15 ng/mL, the pattern of reduction in SF in placebo-randomized patients was similar to that of the everolimus LE group. The HE group achieved the greatest reduction, possibly due to higher C~min~ levels attained by this group. The low frequency of days without seizures observed during the study had a minimal effect on data interpretation. Fewer everolimus-treated patients required rescue medications; 50% of patients received \>2 concomitant AEDs from beginning to end of everolimus treatment with 47% receiving the same AED regimen for ≥1 year. This suggests that efficacy is maintained over a longer period with a reduced need for rescue medications or changes to concomitant AED treatment.

The long-term safety profile of everolimus was consistent with that previously reported in the core phase of this study^[@R9]^ and in other studies of everolimus in TSC-associated clinical settings.^[@R13],[@R14]^ Few clinical trials have assessed the role of mTOR inhibitors for seizures in TSC. This study confirms that AEs observed with prolonged use of everolimus are consistent with established risks, do not overlap with the typical side effects of conventional AEDs, and no new safety issues were found to manifest over time. Stomatitis and mouth ulceration, the primary identified risks associated with everolimus treatment, continued to be the most frequently reported AEs and were the primary cause of dose interruptions or reductions. The incidence of treatment-related AEs by period of emergence did not increase over time with longer exposure to everolimus. However, these results should be interpreted with caution because less than 40% of patients were exposed to everolimus for a period of ≥2 years, whereas approximately 80% of patients were exposed to everolimus for a period of ≥1 year. With extended treatment, an increased incidence and severity of infections (primarily pneumonia) were observed in younger children (\<6 years), which is consistent with the known pattern of pneumonia reported in the general population. Pneumonia is a major cause of morbidity and mortality worldwide in children younger than 5 years in general,^[@R15],[@R16]^ whereas renal disease and SUDEP are considered significant causes of mortality in TSC.^[@R17]^ Two deaths occurred because of pneumonia and septic shock, suspected to be treatment related.

The lack of a placebo arm in the extension phase of the study and the lack of assessments related to change in AEDs are limitations. In addition, these data should be interpreted with caution taking into account patient withdrawals and patients still receiving treatment in the extension phase, resulting in fewer evaluable patients over time for the extension phase of the study. In conclusion, our findings suggest that long-term exposure to everolimus as adjunctive therapy provides a sustained reduction in SF that tends to increase over time. Adverse events were similar to those of previous placebo-controlled trials of everolimus in TSC, with a favorable benefit-risk ratio that improves with ongoing treatment. These results suggest that long-term treatment of TSC-associated refractory seizures with everolimus has a favorable risk-benefit ratio.
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